While low plasma ADA2 levels and elevated TNFα are diagnostic markers for DADA2, immunological screening is essential to avoid delays, especially when pancytopenia is the sole clinical presentation in disorders that impact both marrow cell development and immune function. This evidence concerns the gene ADA2 and deficiency of adenosine deaminase 2.